NASDAQ:AEZS - AEterna Zentaris Stock Price, News & Analysis

$2.08
0.00 (0.00 %)
(As of 08/25/2019 07:18 AM ET)
Today's Range
$2.03
Now: $2.08
$2.11
50-Day Range
$2.07
MA: $2.45
$2.90
52-Week Range
$1.29
Now: $2.08
$5.57
Volume36,755 shs
Average Volume70,068 shs
Market Capitalization$34.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AEZS
CUSIPN/A
Phone843-900-3223

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.90 million
Cash Flow$0.2220 per share
Book Value($0.18) per share

Profitability

Net Income$4.19 million
Net Margins-536.79%

Miscellaneous

EmployeesN/A
Market Cap$34.20 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.


AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) posted its quarterly earnings data on Tuesday, August, 13th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.15. The biopharmaceutical company earned $0.19 million during the quarter, compared to the consensus estimate of $0.20 million. AEterna Zentaris had a negative net margin of 536.79% and a negative return on equity of 1,428.66%. View AEterna Zentaris' Earnings History.

When is AEterna Zentaris' next earnings date?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for AEterna Zentaris.

What price target have analysts set for AEZS?

2 analysts have issued 1 year target prices for AEterna Zentaris' stock. Their predictions range from $2.00 to $3.00. On average, they expect AEterna Zentaris' share price to reach $2.50 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price. View Analyst Price Targets for AEterna Zentaris.

What is the consensus analysts' recommendation for AEterna Zentaris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AEterna Zentaris.

What are Wall Street analysts saying about AEterna Zentaris stock?

Here are some recent quotes from research analysts about AEterna Zentaris stock:
  • 1. HC Wainwright analysts commented, "We maintain our Buy rating of AEZS and our 12-month price target of $5.50 per share. We derive our price target using a risk- adjusted net present value analysis of potential US and EU royalties, discounted at 18%, to reach a total rNPV of $66M for the royalty streams." (8/15/2019)
  • 2. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (3/22/2019)

Has AEterna Zentaris been receiving favorable news coverage?

News headlines about AEZS stock have been trending positive this week, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AEterna Zentaris earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for AEterna Zentaris.

Are investors shorting AEterna Zentaris?

AEterna Zentaris saw a decline in short interest in July. As of July 31st, there was short interest totalling 401,700 shares, a decline of 6.5% from the June 30th total of 429,400 shares. Based on an average daily volume of 112,200 shares, the days-to-cover ratio is presently 3.6 days. Currently, 4.1% of the company's stock are short sold. View AEterna Zentaris' Current Options Chain.

Who are some of AEterna Zentaris' key competitors?

What other stocks do shareholders of AEterna Zentaris own?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:
  • Mr. Michael V. Ward, Pres & CEO (Age 62)
  • Ms. Leslie Auld, Sr. VP & CFO
  • Mr. Brian Garrison, Sr. VP of Global Corp. Operations & Corp. Devel.
  • Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.
  • Mr. Olaf Althaus, GM & MD

Who are AEterna Zentaris' major shareholders?

AEterna Zentaris' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Morgan Stanley (4.18%), BlackRock Inc. (0.28%) and Creative Planning (0.06%).

Which institutional investors are selling AEterna Zentaris stock?

AEZS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley.

Which institutional investors are buying AEterna Zentaris stock?

AEZS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc. and Creative Planning.

How do I buy shares of AEterna Zentaris?

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $2.08.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of $34.20 million and generates $26.90 million in revenue each year. The biopharmaceutical company earns $4.19 million in net income (profit) each year or $0.25 on an earnings per share basis. View Additional Information About AEterna Zentaris.

What is AEterna Zentaris' official website?

The official website for AEterna Zentaris is http://www.aezsinc.com/.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 843-900-3223 or via email at [email protected]


MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  617
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Featured Article: What is Compound Interest?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel